Delayed reduction of hepatitis B viral load and dynamics of adefovir-resistant variants during adefovir plus entecavir combination rescue therapy

International Journal of Medical Sciences

Volumn 12, Issue 5, 2015, Pages 416-422

  Wang, Yang ^a   Liu, Shuang ^a   Chen, Yu ^a   Zheng, Sujun ^a   Zhou, Li ^a   Lu, Fengmin ^b   Duan, Zhongping ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Adefovir; Entecavir; Hepatitis B virus; Rescue therapy; Resistance

Indexed keywords

ADEFOVIR; ENTECAVIR; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; GUANINE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; CHRONIC HEPATITIS B; COHORT ANALYSIS; DRUG RESPONSE; FEMALE; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT MONITORING; PYROSEQUENCING; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; HEPATITIS B, CHRONIC; MIDDLE AGED; MUTATION; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADENINE; ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION; ORGANOPHOSPHONATES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84930209100     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.11687     Document Type: Article

References (38)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and en-demicity. Vaccine. 2012; 30: 2212-9.
2. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007; 5: 921-31.
3. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009; 137: 1593-608.
4. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001; 34: 785-91.
5. Rodriguez C, Chevaliez S, Bensadoun P, Pawlotsky JM. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology. 2013; 58: 890-901.
6. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, et al. Tenofo-vir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 2011; 60: 247-54.
7. van Bommel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B vi-rus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010; 51: 73-80.
8. Deterding K, Manns MP, Wedemeyer H. Does the presence of adefo-vir-resistant variants lead to failure of tenofovir monotherapy? Journal of hepatology. 2008; 49: 862-3.
9. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003; 348: 808-16.
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003; 348: 800-7.
11. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005; 352: 2673-81.
12. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131: 1743-51.
13. Minde Z, Yimin M, Guangbi Y, JinLin H, Hao W, Hong R, et al. Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. Liver international: official journal of the International Association for the Study of the Liver. 2012; 32: 137-46.
14. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003; 125: 292-7.
15. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. Journal of hepatology. 2008; 48: 747-55.
16. Kang SH, Yim HJ, Kim HR, Kang K, Suh SJ, Lee HJ, et al. Comparison of Lamivudine Plus Adefovir Therapy Versus Entecavir With or Without Ade-fovir Therapy for Adefovir-resistant Chronic Hepatitis B. J Clin Gastroenterol. 2014; 48: 889-95.
17. Liaw Y-F, Kao J-H, Piratvisuth T, Chan HLY, Chien R-N, Liu C-J, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6: 531-61.
18. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50: 661-2.
19. European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57: 167-85.
20. Pallier C, Rodriguez C, Brillet R, Nordmann P, Hezode C, Pawlotsky JM. Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology. 2009; 49: 50-9.
21. Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, et al. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants. Antivir Ther. 2012; 17: 701-9.
22. Ko SY, Kim BK, Kwon SY, Kim KH, Kim JH, Choe WH, et al. Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment. World journal of gastroenterology: WJG. 2012; 18: 6437-46; discussion p 45.
23. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45: 507-39.
24. Lee GH, Inoue M, Toh JK, Chong RH, Aung MO, Koay ES, et al. Two-step evolution of the hepatitis B drug-resistant mutations in a patient who developed primary entecavir resistance. Liver international: official journal of the International Association for the Study of the Liver. 2013; 33: 642-6.
25. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007; 46: 254-65.
26. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology. 2009; 49: 72-9.
27. Gane EJ. The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatology international. 2008; 2: 304-7.
28. Lu HY, Zhuang LW, Yu YY, Si CW. Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients. J Viral Hepat. 2010; 17 Suppl 1: 59-65.
29. Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA, Licari T, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology. 2011; 53: 1854-63.
30. Carrouee-Durantel S, Durantel D, Werle-Lapostolle B, Pichoud C, Naesens L, Neyts J, et al. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. Antivir Ther. 2008; 13: 381-8.
31. Hezode C, Chevaliez S, Bouvier-Alias M, Roudot-Thoraval F, Brillet R, Zafrani ES, et al. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J Hepatol. 2007; 46: 791-6.
32. Chang UI, Lee YC, Wie SH, Jang JW, Bae SH, Choi JY, et al. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy. Journal of medical virology. 2007; 79: 902-10.
33. Choe WH, Kwon SY, Kim BK, Ko SY, Yeon JE, Byun KS, et al. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. Liver Int. 2008; 28: 814-20.
34. Lee YB, Lee JH, Lee DH, Cho H, Ahn H, Choi WM, et al. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrob Agents Chemother. 2014; 58: 6710-6.
35. van Bommel F, Trojan J, Deterding K, Wedemeyer H, Wasmuth HE, Huppe D, et al. Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy. Antivir Ther. 2012; 17: 1049-58.
36. Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol. 2003; 39: 1085-9.
37. Deng XL, Li QL, Guo JJ. Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy. Virus genes. 2013; 47: 1-9.
38. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003; 124: 105-17.